Genome editing startup Beam Therapeutics was already trying to go public in a tough market for biotech companies. This week brought a new complication: explaining to potential investors why your co-founder just launched a rival startup.

Beam is based on a newfangled approach to CRISPR called base editing, invented by Broad Institute researcher David Liu, that allows scientists to change individual letters of DNA. The two-year-old company, which counts Liu as a co-founder, filed to raise $100 million in an initial public offering in September.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It seems to me that David Liu is severely lacking in ethics. It seems to me that greed is the only explanation as to why he thought it better to launch two companies. 🙄